CX Institutional Purchases New Stake in Alphatec Holdings, Inc. (NASDAQ:ATEC)

CX Institutional bought a new position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 27,080 shares of the medical technology company's stock, valued at approximately $275,000.

Other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its position in shares of Alphatec by 38,433.3% in the first quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company's stock valued at $228,000 after acquiring an additional 2,306 shares during the period. Comerica Bank boosted its position in shares of Alphatec by 66.8% in the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after acquiring an additional 1,248 shares during the period. Quarry LP boosted its position in shares of Alphatec by 79.2% in the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock valued at $49,000 after acquiring an additional 2,375 shares during the period. Lazard Asset Management LLC bought a new stake in shares of Alphatec in the fourth quarter valued at approximately $76,000. Finally, AlphaQuest LLC bought a new position in Alphatec in the fourth quarter worth $80,000. Institutional investors own 66.35% of the company's stock.

Wall Street Analyst Weigh In

ATEC has been the subject of several research reports. Piper Sandler reaffirmed an "overweight" rating and issued a $15.00 target price (up from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. Wall Street Zen raised Alphatec from a "sell" rating to a "hold" rating in a research report on Friday, February 28th. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 target price on shares of Alphatec in a research report on Monday, April 14th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $16.00 target price on shares of Alphatec in a research report on Friday, May 2nd. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $17.89.

Insider Activity

In other news, EVP Craig E. Hunsaker sold 186,122 shares of the firm's stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $12.34, for a total value of $2,296,745.48. Following the completion of the sale, the executive vice president now directly owns 1,463,896 shares in the company, valued at approximately $18,064,476.64. This trade represents a 11.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Scott Lish sold 12,000 shares of the firm's stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $12.12, for a total value of $145,440.00. Following the completion of the transaction, the chief operating officer now owns 826,251 shares in the company, valued at approximately $10,014,162.12. This represents a 1.43% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 271,338 shares of company stock worth $3,381,584. 20.90% of the stock is owned by corporate insiders.

Alphatec Price Performance

Alphatec stock traded down $0.31 during mid-day trading on Friday, hitting $11.06. 1,994,477 shares of the company were exchanged, compared to its average volume of 2,060,228. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The business has a fifty day moving average of $11.68 and a 200 day moving average of $10.82. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $13.14. The company has a market capitalization of $1.62 billion, a PE ratio of -8.64 and a beta of 1.10.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.23). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The company had revenue of $169.18 million for the quarter, compared to analyst estimates of $167.57 million. During the same quarter in the prior year, the company earned ($0.34) earnings per share. The business's revenue was up 22.2% compared to the same quarter last year. As a group, sell-side analysts expect that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.